AMSTERDAM, August 14, 2014 /PRNewswire/ --
Elsevier, a world-leading provider of scientific, technical and
medical information products and services, today announced the
highlights of its journal Impact Factor performance in 2013.
According to the 2013 Journal Citation Reports® (JCR)
published by Thomson Reuters, Elsevier saw 61% of its journal
Impact Factors increase from 2012 to 2013, well ahead of the
aggregate across all other journals at 55%. Furthermore, 21% of
Elsevier journals are in the top 10% of their subject category.
In 2013 Elsevier journals occupied the top position by Impact
Factor in 61 subject categories, up from 58 in 2012. In addition,
14 Elsevier journals have risen to the top of their subject
category and 40 journals have received an impact factor for the
first time. Among these is Nano Energy, which published its
first issue in 2012 and received an impressive first impact factor
of 10.211.
Philippe Terheggen, Managing
Director Journals at Elsevier, said: "These results tell me that
the authors, editors and reviewers that our journal publishers work
with, continue to excel at what they do, and manage to improve the
reputation of these journals year upon year. These promising
outcomes support my view that we are playing an important role in
advancing research, and confirm that the continuous investments we
make to help our researchers in scientific, technical and health
areas to improve content quality are effective. It should be said,
however, that the Impact Factor does not tell the whole story, and
that journal quality can and should be measured in a variety of
ways. That's why we've developed alternative journal metrics, among
which Source Normalized Impact per Paper (SNIP) and the SCImago
Journal Rank (SJR) for all 20,000+ journal titles in the Scopus
database. These metrics provide end-users with a variety of
indicators of journal performance. We will continue to develop new
journal metrics to ultimately create the broadest possible basis
for measuring the contribution and impact of journals, articles, or
authors, in the broadest possible sense."
Flagship titles and society journals
The Impact Factor of The Lancet rose from 39.060 to 39.207,
and its three specialty daughter journals The Lancet Oncology,
The Lancet Neurology and The Lancet Infectious Diseases
retained their high-ranking positions in their respective subject
categories.
Cell, the flagship journal of Cell Press, saw its Impact
Factor increase once again, from 31.957 in 2012 to 33.116 in 2013,
retaining its position as one of the top biomedical research
journals. Overall, 65% of the 28 Cell Press subscription
journals showed increases in Impact Factor with 6 of the 14 Trends
review titles increasing by greater than 10%. Cell
Reports, a high-profile open-access journal from Cell Press
that launched in 2012 and celebrated the publication of its
1000th article in May
2014, has established itself with an impressive first Impact
Factor of 7.207.
Of the 372 titles in the JCR that Elsevier publishes on behalf
of societies, 220, or 59%, showed a rise in their Impact Factors.
The Journal of the American College of Cardiology increased
its Impact Factor by 9% and leaps two places to rank first in
"Cardiac & Cardiovascular Systems" - and its specialty daughter
journal JACC: Cardiovascular Imaging - increased its Impact
Factor by 13% to jump three places to the top position in
"Radiology, Nuclear Medicine & Medical Imaging".
The Impact Factor helps evaluate a journal's impact compared to
others in the same field by measuring the frequency with which
recent articles in a journal have been cited in a particular year:
the 2013 Impact Factor takes into account citations in 2013 to
papers published in 2011 and 2012.
---
About Elsevier
Elsevier is a world-leading provider of information solutions
that enhance the performance of science, health, and technology
professionals, empowering them to make better decisions, deliver
better care, and sometimes make groundbreaking discoveries that
advance the boundaries of knowledge and human progress. Elsevier
provides web-based, digital solutions - among them
ScienceDirect, Scopus, Elsevier Research Intelligence, and
ClinicalKey - and publishes nearly 2,200 journals, including The
Lancet and Cell, and over 25,000 book titles, including a number of
iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading
provider of professional information solutions in the Science,
Medical, Legal and Risk and Business sectors, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols
are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange).
Media contact
Harald Boersma
Director Corporate Relations, Elsevier
+31-20-485-27-36
H.boersma@elsevier.com